These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. [DNA vaccines against allergy]. Sato Y; Kasukawa R Nihon Rinsho; 2000 Jun; 58(6):1307-14. PubMed ID: 10879058 [TBL] [Abstract][Full Text] [Related]
7. Strategies for the development of safe and effective DNA vaccines for allergy treatment. Hartl A; Weiss R; Hochreiter R; Scheiblhofer S; Bauer R; Valenta R; Ferreira F; Leitner W; Thalhamer J Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M; 2003; (94):279-98; discussion 299. PubMed ID: 15119049 [TBL] [Abstract][Full Text] [Related]
8. Progress in the development of new methods of immunotherapy: potential application of immunostimulatory DNA-conjugated to allergens for treatment of allergic respiratory conditions. Creticos PS; Lichtenstein LM Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M; 2003; (94):304-12; discussion 312-3. PubMed ID: 15119051 [TBL] [Abstract][Full Text] [Related]
9. Novel vaccines and adjuvants for allergen-specific immunotherapy. Crameri R; Rhyner C Curr Opin Immunol; 2006 Dec; 18(6):761-8. PubMed ID: 17010585 [TBL] [Abstract][Full Text] [Related]
12. Genetic allergen modification in the development of novel approaches to specific immunotherapy. Mutschlechner S; Deifl S; Bohle B Clin Exp Allergy; 2009 Nov; 39(11):1635-42. PubMed ID: 19624521 [TBL] [Abstract][Full Text] [Related]
13. DNA vaccine encoding Der p 2 allergen generates immunologic protection in recombinant Der p 2 allergen-induced allergic airway inflammation mice model. Li GP; Liu ZG; Qiu J; Ran PX; Zhong NS Chin Med J (Engl); 2005 Apr; 118(7):534-40. PubMed ID: 15820083 [TBL] [Abstract][Full Text] [Related]
14. Vaccinations with T-helper type 1 directing adjuvants have different suppressive effects on the development of allergen-induced T-helper type 2 responses. Trujillo-Vargas CM; Mayer KD; Bickert T; Palmetshofer A; Grunewald S; Ramirez-Pineda JR; Polte T; Hansen G; Wohlleben G; Erb KJ Clin Exp Allergy; 2005 Aug; 35(8):1003-13. PubMed ID: 16120081 [TBL] [Abstract][Full Text] [Related]
15. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Senti G; Johansen P; Haug S; Bull C; Gottschaller C; Müller P; Pfister T; Maurer P; Bachmann MF; Graf N; Kündig TM Clin Exp Allergy; 2009 Apr; 39(4):562-70. PubMed ID: 19226280 [TBL] [Abstract][Full Text] [Related]
16. Strategies for converting allergens into hypoallergenic vaccine candidates. Vrtala S; Focke-Tejkl M; Swoboda I; Kraft D; Valenta R Methods; 2004 Mar; 32(3):313-20. PubMed ID: 14962766 [TBL] [Abstract][Full Text] [Related]
17. Immune mechanisms of allergen-specific sublingual immunotherapy. Moingeon P; Batard T; Fadel R; Frati F; Sieber J; Van Overtvelt L Allergy; 2006 Feb; 61(2):151-65. PubMed ID: 16409190 [TBL] [Abstract][Full Text] [Related]
18. Molecular approaches for new vaccines against allergy. Niederberger V; Valenta R Expert Rev Vaccines; 2006 Feb; 5(1):103-10. PubMed ID: 16451112 [TBL] [Abstract][Full Text] [Related]